- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Dostarlimab, Pembrolizumab, Chemotherapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Denver, North Carolina • Cincinnati, Ohio • Fairfax, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 750
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
- Interventions
- filgrastim, docetaxel, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2006
- U.S. locations
- 35
- States / cities
- La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Paclitaxel, Gemcitabine, Avastin
- Drug · Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Squamous Non Small Cell Lung Cancer
- Interventions
- HLX10, carboplatin and nab paclitaxel, Placebo
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 537 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
- Interventions
- tucatinib, trastuzumab, fulvestrant
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more
- Conditions
- Non-small Cell Lung Cancer Stage IIIB/IV, Non-small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung
- Interventions
- metformin, carbohydrate restricted diet
- Drug · Behavioral
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 4
- States / cities
- New York, New York
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
- Interventions
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
- Drug
- Lead sponsor
- Neonc Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more
- Conditions
- Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC
- Interventions
- TH-4000 (Tarloxotinib)
- Drug
- Lead sponsor
- Rain Oncology Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Rosa, California • Aurora, Colorado + 8 more
- Conditions
- Lung Cancer
- Interventions
- Avastin, Tarceva
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Houston, Texas
- Conditions
- Non Small Cell Lung Cancer, c-MET
- Interventions
- Telisotuzumab Vedotin, Docetaxel
- Biological · Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 768 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 46 more
- Conditions
- NSCLC, Stage IIIA (N2)
- Interventions
- Gemcitabine, Cisplatin, Bevacizumab, Surgery, Etoposide
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
- Interventions
- XmAb®23104, Yervoy® (ipilimumab)
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 18
- States / cities
- San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more
- Conditions
- Solid Tumors
- Interventions
- RMC-5552
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Irvine, California • Sacramento, California • San Francisco, California + 5 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 84
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage, B7H3, Prostate Cancer, HNSCC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Head Neck Cancer Squamous Cell Metastatic, ESCC or Esophageal Adenosquamous Carcinoma, CRC, CRC (Colorectal Cancer)
- Interventions
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Drug
- Lead sponsor
- Aktis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 2
- States / cities
- Miami, Florida • Houston, Texas
- Conditions
- Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Berzosertib, Biospecimen Collection, Carboplatin, Computed Tomography, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 34
- States / cities
- Los Angeles, California • Newport Beach, California • Aventura, Florida + 25 more
- Conditions
- Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
- Interventions
- ⁸⁹Zr-Df-IAB22M2C Infusion
- Drug
- Lead sponsor
- ImaginAb, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Lung Cancer
- Interventions
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001
- U.S. locations
- 57
- States / cities
- Loma Linda, California • Pomona, California • New London, Connecticut + 46 more
- Conditions
- Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
- Interventions
- PF-07209960
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
- Conditions
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Interventions
- CBP501 + Cisplatin + Pemetrexed, Cisplatin + Pemetrexed
- Drug
- Lead sponsor
- CanBas Co. Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 3
- States / cities
- Las Vegas, Nevada • Hershey, Pennsylvania • Dallas, Texas
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
- Interventions
- PM01183 + paclitaxel +/- bevacizumab
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
- Interventions
- PF-07820435, Sasanlimab
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Sarasota, Florida • Grand Rapids, Michigan • Nashville, Tennessee
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis
- Interventions
- Bevacizumab, Pemetrexed, Vitamin B12, Folate, Dexamethasone
- Drug
- Lead sponsor
- Heather Wakelee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 4
- States / cities
- Stanford, California • Lebanon, New Hampshire • Voorhees Township, New Jersey + 1 more